2.23 USD
+0.04 (+1.83%)
Last: Feb 2, 2026, 08:00 PM
Overall SPRO gets a fundamental rating of 4 out of 10. We evaluated SPRO against 524 industry peers in the Biotechnology industry. While SPRO seems to be doing ok healthwise, there are quite some concerns on its profitability. SPRO has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- SPRO had negative earnings in the past year.
- In the past year SPRO has reported a negative cash flow from operations.
- SPRO had negative earnings in 4 of the past 5 years.
- In the past 5 years SPRO always reported negative operating cash flow.
1.2 Ratios
- SPRO has a Return On Assets of -80.92%. This is in the lower half of the industry: SPRO underperforms 68.32% of its industry peers.
- SPRO's Return On Equity of -165.46% is on the low side compared to the rest of the industry. SPRO is outperformed by 65.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -80.92% | ||
| ROE | -165.46% | ||
| ROIC | N/A |
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for SPRO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- SPRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for SPRO has been increased compared to 1 year ago.
- The number of shares outstanding for SPRO has been increased compared to 5 years ago.
- SPRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- SPRO has an Altman-Z score of -10.89. This is a bad value and indicates that SPRO is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of SPRO (-10.89) is worse than 73.47% of its industry peers.
- SPRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.89 |
ROIC/WACCN/A
WACC8.9%
2.3 Liquidity
- SPRO has a Current Ratio of 3.83. This indicates that SPRO is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 3.83, SPRO is in line with its industry, outperforming 45.99% of the companies in the same industry.
- SPRO has a Quick Ratio of 3.83. This indicates that SPRO is financially healthy and has no problem in meeting its short term obligations.
- SPRO has a Quick ratio (3.83) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.83 | ||
| Quick Ratio | 3.83 |
3. Growth
3.1 Past
- The earnings per share for SPRO have decreased strongly by -1228.57% in the last year.
- The Revenue for SPRO has decreased by -61.91% in the past year. This is quite bad
- The Revenue has been growing by 21.46% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-1228.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.38%
Revenue 1Y (TTM)-61.91%
Revenue growth 3Y37.99%
Revenue growth 5Y21.46%
Sales Q2Q%-59.6%
3.2 Future
- Based on estimates for the next years, SPRO will show a very strong growth in Earnings Per Share. The EPS will grow by 20.25% on average per year.
- Based on estimates for the next years, SPRO will show a very strong growth in Revenue. The Revenue will grow by 20.52% on average per year.
EPS Next Y91.97%
EPS Next 2Y59.31%
EPS Next 3Y13.29%
EPS Next 5Y20.25%
Revenue Next Year-34.56%
Revenue Next 2Y-85.67%
Revenue Next 3Y-56.53%
Revenue Next 5Y20.52%
3.3 Evolution
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for SPRO. In the last year negative earnings were reported.
- SPRO is valuated cheaply with a Price/Forward Earnings ratio of 3.26.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of SPRO indicates a rather cheap valuation: SPRO is cheaper than 99.43% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 25.64, SPRO is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.26 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- SPRO's earnings are expected to grow with 13.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y59.31%
EPS Next 3Y13.29%
5. Dividend
5.1 Amount
- SPRO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:SPRO (2/2/2026, 8:00:03 PM)
2.23
+0.04 (+1.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners16.1%
Inst Owner Change1.43%
Ins Owners2.43%
Ins Owner Change-0.73%
Market Cap125.64M
Revenue(TTM)40.55M
Net Income(TTM)-43.84M
Analysts43.33
Price Target4.08 (82.96%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)70.64%
Min EPS beat(2)49.02%
Max EPS beat(2)92.26%
EPS beat(4)3
Avg EPS beat(4)44.13%
Min EPS beat(4)-20.18%
Max EPS beat(4)92.26%
EPS beat(8)6
Avg EPS beat(8)100.4%
EPS beat(12)10
Avg EPS beat(12)186.6%
EPS beat(16)11
Avg EPS beat(16)138.03%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.09%
EPS NY rev (1m)0%
EPS NY rev (3m)87.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)26.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 3.26 | ||
| P/S | 3.1 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.74 | ||
| P/tB | 4.74 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.79
EYN/A
EPS(NY)0.68
Fwd EY30.65%
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0.72
BVpS0.47
TBVpS0.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -80.92% | ||
| ROE | -165.46% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-28.91%
ROA(5y)-38.11%
ROE(3y)-62.83%
ROE(5y)-69.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.83 | ||
| Quick Ratio | 3.83 | ||
| Altman-Z | -10.89 |
F-Score3
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1228.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.38%
EPS Next Y91.97%
EPS Next 2Y59.31%
EPS Next 3Y13.29%
EPS Next 5Y20.25%
Revenue 1Y (TTM)-61.91%
Revenue growth 3Y37.99%
Revenue growth 5Y21.46%
Sales Q2Q%-59.6%
Revenue Next Year-34.56%
Revenue Next 2Y-85.67%
Revenue Next 3Y-56.53%
Revenue Next 5Y20.52%
EBIT growth 1Y-3984.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-195.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-195.49%
OCF growth 3YN/A
OCF growth 5YN/A
SPERO THERAPEUTICS INC / SPRO FAQ
What is the ChartMill fundamental rating of SPERO THERAPEUTICS INC (SPRO) stock?
ChartMill assigns a fundamental rating of 4 / 10 to SPRO.
Can you provide the valuation status for SPERO THERAPEUTICS INC?
ChartMill assigns a valuation rating of 4 / 10 to SPERO THERAPEUTICS INC (SPRO). This can be considered as Fairly Valued.
What is the profitability of SPRO stock?
SPERO THERAPEUTICS INC (SPRO) has a profitability rating of 0 / 10.
What is the financial health of SPERO THERAPEUTICS INC (SPRO) stock?
The financial health rating of SPERO THERAPEUTICS INC (SPRO) is 6 / 10.